A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
REGULATORY
Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
A business suspension order issued to Choseido Pharmaceutical over its manufacturing issues could further stymie the already-slow generic penetration in its home prefecture of Tokushima, possibly steering doctors and patients away from these medicines. On October 11, Tokushima prefectural authorities…
To read the full story
Related Article
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
- One-Month Business Suspension Order Likely for Choseido over Generic Recalls
September 24, 2021
- Shipments of 64 Choseido-Made Products Now Adjusted or Halted
August 20, 2021
- Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
August 18, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
REGULATORY
- MHLW Council Deems Public Knowledge-Based Filings Acceptable for 8 Fertility Treatment Indications
January 28, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…